{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:59:31Z","timestamp":1764961171206,"version":"3.46.0"},"reference-count":35,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T00:00:00Z","timestamp":1524614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neuromyelitis optica (NMO), also known as Devic\u2019s disease, is an autoimmune disorder of the central nervous system (CNS) in which immune system cells and antibodies primarily attack the optic nerves and the spinal cord. OX40 (CD134) is a tumor necrosis factor (TNF)-receptor family member expressed primarily on activated CD4\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cells. In an autoimmune disease, OX40 is typically up-regulated at sites of inflammation, and increases in the number of peripheral CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cells expressing OX40. OX40 and its ligand OX40L are key TNF members that augment T-cell expansion, cytokine production, and promote T-cell survival. The aim of this study was to evaluate and compare of\n                    <jats:italic>OX40<\/jats:italic>\n                    gene expression and its serum levels in patients with NMO and healthy controls. Twenty sex-\/age-matched healthy controls (HC) (median age = 32 years, 15 females\/5 males) were engaged for the present study. Expression of\n                    <jats:italic>OX40<\/jats:italic>\n                    at the transcript level and serum protein levels were measured by quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assays, respectively. The results indicated\n                    <jats:italic>OX40<\/jats:italic>\n                    expression in patients was significantly lower than in healthy controls (p = 0.001). However, the serum level of OX40 was not significantly different between groups (p = 0.37). In addition, the results indicated that CD134 expression was not age-related (p = 0.041). Overall, this study suggests to us that OX40 levels are not a suitable marker for diagnosis or treatment of NMO.\n                  <\/jats:p>","DOI":"10.1515\/bmc-2019-0007","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T05:02:46Z","timestamp":1555477366000},"page":"62-67","source":"Crossref","is-referenced-by-count":0,"title":["Expression of OX40 Gene and its Serum Levels in Neuromyelitis Optica Patients"],"prefix":"10.1515","volume":"10","author":[{"given":"Parya","family":"Alidadiani","sequence":"first","affiliation":[{"name":"Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Physiology, Applied Physiology Research Center, Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahid","family":"Eskandari","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Physiology, Applied Physiology Research Center, Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[{"name":"Isfahan Neuroscience Research Center, Department of Neurology, Alzahra Hospital, Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arezou","family":"Dabiri","sequence":"additional","affiliation":[{"name":"Department of Immunology, International Campus, Shahid Sadoughi University of Medical Sciences , Yazd , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Manian","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Medicine, Iran University of Medical Sciences , Tehran , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Jahanbani-Ardakani","sequence":"additional","affiliation":[{"name":"Isfahan Medical Students Research Center (IMSRC), Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omid","family":"Mirmosayyeb","sequence":"additional","affiliation":[{"name":"Isfahan Neuroscience Research Center, Department of Neurology, Alzahra Hospital, Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2013;84(8):922-30.10.1136\/jnnp-2012-30231023142960","key":"2025120518082443756_j_bmc-2019-0007_ref_001_w2aab3b7b6b1b6b1ab1b6b1Aa","DOI":"10.1136\/jnnp-2012-302310"},{"doi-asserted-by":"crossref","unstructured":"Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Current opinion in neurology. 2007;20(3):255-60.1749561710.1097\/WCO.0b013e32814f1c6b","key":"2025120518082443756_j_bmc-2019-0007_ref_002_w2aab3b7b6b1b6b1ab1b6b2Aa","DOI":"10.1097\/WCO.0b013e32814f1c6b"},{"doi-asserted-by":"crossref","unstructured":"Morrow MJ, Wingerchuk D. Neuromyelitis optica. Journal of Neuro-Ophthalmology. 2012;32(2):154-66.10.1097\/WNO.0b013e31825662f1","key":"2025120518082443756_j_bmc-2019-0007_ref_003_w2aab3b7b6b1b6b1ab1b6b3Aa","DOI":"10.1097\/WNO.0b013e31825662f1"},{"doi-asserted-by":"crossref","unstructured":"Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of neurology. 2014;261(1):1-16.10.1007\/s00415-013-7169-7","key":"2025120518082443756_j_bmc-2019-0007_ref_004_w2aab3b7b6b1b6b1ab1b6b4Aa","DOI":"10.1007\/s00415-013-7169-7"},{"doi-asserted-by":"crossref","unstructured":"Drori T, Chapman J. Diagnosis and classification of neuromyelitis optica (Devic\u2019s syndrome). Autoimmunity reviews. 2014;13(4-5):531-3.2442419710.1016\/j.autrev.2014.01.034","key":"2025120518082443756_j_bmc-2019-0007_ref_005_w2aab3b7b6b1b6b1ab1b6b5Aa","DOI":"10.1016\/j.autrev.2014.01.034"},{"doi-asserted-by":"crossref","unstructured":"Akiba H, Oshima H, Takeda K, Atsuta M, Nakano H, Nakajima A, et al. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. The Journal of Immunology. 1999;162(12):7058-66.","key":"2025120518082443756_j_bmc-2019-0007_ref_006_w2aab3b7b6b1b6b1ab1b6b6Aa","DOI":"10.4049\/jimmunol.162.12.7058"},{"doi-asserted-by":"crossref","unstructured":"Ishii N, Takahashi T, Soroosh P, Sugamura K. OX40\u2013 OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Advances in immunology. 105: Elsevier; 2010. p. 63-98.","key":"2025120518082443756_j_bmc-2019-0007_ref_007_w2aab3b7b6b1b6b1ab1b6b7Aa","DOI":"10.1016\/S0065-2776(10)05003-0"},{"doi-asserted-by":"crossref","unstructured":"Kaur D, Brightling C. OX40\/OX40 ligand interactions in T-cell regulation and asthma. Chest. 2012;141(2):494-9.10.1378\/chest.11-173022315115","key":"2025120518082443756_j_bmc-2019-0007_ref_008_w2aab3b7b6b1b6b1ab1b6b8Aa","DOI":"10.1378\/chest.11-1730"},{"doi-asserted-by":"crossref","unstructured":"Webb GJ, Hirschfield GM, Lane PJ. OX40, OX40L and autoimmunity: a comprehensive review. Clinical reviews in allergy & immunology. 2016;50(3):312-32.2621516610.1007\/s12016-015-8498-3","key":"2025120518082443756_j_bmc-2019-0007_ref_009_w2aab3b7b6b1b6b1ab1b6b9Aa","DOI":"10.1007\/s12016-015-8498-3"},{"doi-asserted-by":"crossref","unstructured":"Sand IK. Neuromyelitis optica spectrum disorders. CONTINUUM: Lifelong Learning in Neurology. 2016;22(3, Multiple Sclerosis and Other Demyelinating Diseases):864-96.","key":"2025120518082443756_j_bmc-2019-0007_ref_010_w2aab3b7b6b1b6b1ab1b6c10Aa","DOI":"10.1212\/CON.0000000000000337"},{"doi-asserted-by":"crossref","unstructured":"Sato DK, Lana\u2010Peixoto MA, Fujihara K, de Seze J. Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status. Brain Pathology. 2013;23(6):647-60.10.1111\/bpa.12087","key":"2025120518082443756_j_bmc-2019-0007_ref_011_w2aab3b7b6b1b6b1ab1b6c11Aa","DOI":"10.1111\/bpa.12087"},{"doi-asserted-by":"crossref","unstructured":"Linch SN, McNamara MJ, Redmond WL. OX40 agonists and combination immunotherapy: putting the pedal to the metal. Frontiers in oncology. 2015;5:34.25763356","key":"2025120518082443756_j_bmc-2019-0007_ref_012_w2aab3b7b6b1b6b1ab1b6c12Aa","DOI":"10.3389\/fonc.2015.00034"},{"doi-asserted-by":"crossref","unstructured":"Griseri T, Asquith M, Thompson C, Powrie F. OX40 is required for regulatory T cell\u2013mediated control of colitis. Journal of Experimental Medicine. 2010;207(4):699-709.10.1084\/jem.20091618","key":"2025120518082443756_j_bmc-2019-0007_ref_013_w2aab3b7b6b1b6b1ab1b6c13Aa","DOI":"10.1084\/jem.20091618"},{"doi-asserted-by":"crossref","unstructured":"Sitrin J, Suto E, Wuster A, Eastham-Anderson J, Kim JM, Austin CD, et al. The Ox40\/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB\/W F1 Mice. Journal of immunology (Baltimore, Md : 1950). 2017;199(4):1238-49.","key":"2025120518082443756_j_bmc-2019-0007_ref_014_w2aab3b7b6b1b6b1ab1b6c14Aa","DOI":"10.4049\/jimmunol.1700608"},{"doi-asserted-by":"crossref","unstructured":"Patschan S, Dolff S, Kribben A, D\u00fcrig J, Patschan D, Wilde B, et al. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clinical & Experimental Immunology. 2006;145(2):235-42.10.1111\/j.1365-2249.2006.03141.x","key":"2025120518082443756_j_bmc-2019-0007_ref_015_w2aab3b7b6b1b6b1ab1b6c15Aa","DOI":"10.1111\/j.1365-2249.2006.03141.x"},{"doi-asserted-by":"crossref","unstructured":"Zander RA, Obeng-Adjei N, Guthmiller JJ, Kulu DI, Li J, Ongoiba A, et al. PD-1 co-inhibitory and OX40 co-stimulatory crosstalk regulates helper T cell differentiation and anti-Plasmodium humoral immunity. Cell host & microbe. 2015;17(5):628-41.2589135710.1016\/j.chom.2015.03.007","key":"2025120518082443756_j_bmc-2019-0007_ref_016_w2aab3b7b6b1b6b1ab1b6c16Aa","DOI":"10.1016\/j.chom.2015.03.007"},{"doi-asserted-by":"crossref","unstructured":"Kroemer A, Xiao X, Vu MD, Gao W, Minamimura K, Chen M, et al. OX40 controls functionally different T cell subsets and their resistance to depletion therapy. The Journal of Immunology. 2007;179(8):5584-91.10.4049\/jimmunol.179.8.5584","key":"2025120518082443756_j_bmc-2019-0007_ref_017_w2aab3b7b6b1b6b1ab1b6c17Aa","DOI":"10.4049\/jimmunol.179.8.5584"},{"doi-asserted-by":"crossref","unstructured":"Compaan DM, Hymowitz SG. The crystal structure of the costimulatory OX40-OX40L complex. Structure. 2006;14(8):1321-30.10.1016\/j.str.2006.06.01516905106","key":"2025120518082443756_j_bmc-2019-0007_ref_018_w2aab3b7b6b1b6b1ab1b6c18Aa","DOI":"10.1016\/j.str.2006.06.015"},{"doi-asserted-by":"crossref","unstructured":"Jenkins SJ, Perona-Wright G, Worsley AG, Ishii N, MacDonald AS. Dendritic cell expression of OX40 ligand acts as a costimulatory, not polarizing, signal for optimal Th2 priming and memory induction in vivo. The Journal of Immunology. 2007;179(6):3515-23.10.4049\/jimmunol.179.6.3515","key":"2025120518082443756_j_bmc-2019-0007_ref_019_w2aab3b7b6b1b6b1ab1b6c19Aa","DOI":"10.4049\/jimmunol.179.6.3515"},{"unstructured":"Lei W, Zeng D-X, Zhu C-H, Liu G-Q, Zhang X-Q, Wang C-G, et al. The upregulated expression of OX40\/OX40L and their promotion of T cells proliferation in the murine model of asthma. Journal of thoracic disease. 2014;6(7):979.25093096","key":"2025120518082443756_j_bmc-2019-0007_ref_020_w2aab3b7b6b1b6b1ab1b6c20Aa"},{"doi-asserted-by":"crossref","unstructured":"Montler R, Bell RB, Thalhofer C, Leidner R, Feng Z, Fox BA, et al. OX40, PD\u20101 and CTLA\u20104 are selectively expressed on tumor\u2010infiltrating T cells in head and neck cancer. Clinical & translational immunology. 2016;5(4):e70.2719511310.1038\/cti.2016.16","key":"2025120518082443756_j_bmc-2019-0007_ref_021_w2aab3b7b6b1b6b1ab1b6c21Aa","DOI":"10.1038\/cti.2016.16"},{"doi-asserted-by":"crossref","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212 \u0394\u0394CT method. methods. 2001;25(4):402-8.10.1006\/meth.2001.1262","key":"2025120518082443756_j_bmc-2019-0007_ref_022_w2aab3b7b6b1b6b1ab1b6c22Aa","DOI":"10.1006\/meth.2001.1262"},{"doi-asserted-by":"crossref","unstructured":"Wong ML, Medrano JF. Real-time PCR for mRNA quantitation. Biotechniques. 2005;39(1):75-85.10.2144\/05391RV0116060372","key":"2025120518082443756_j_bmc-2019-0007_ref_023_w2aab3b7b6b1b6b1ab1b6c23Aa","DOI":"10.2144\/05391RV01"},{"doi-asserted-by":"crossref","unstructured":"Blanc F, Noblet V, Jung B, Rousseau F, Renard F, Bourre B, et al. White matter atrophy and cognitive dysfunctions in neuromyelitis optica. PLoS One. 2012;7(4):e33878.2250926410.1371\/journal.pone.0033878","key":"2025120518082443756_j_bmc-2019-0007_ref_024_w2aab3b7b6b1b6b1ab1b6c24Aa","DOI":"10.1371\/journal.pone.0033878"},{"doi-asserted-by":"crossref","unstructured":"Kimura A, Kishimoto T. IL-6: regulator of Treg\/Th17 balance. European journal of immunology. 2010;40(7):1830-5.10.1002\/eji.20104039120583029","key":"2025120518082443756_j_bmc-2019-0007_ref_025_w2aab3b7b6b1b6b1ab1b6c25Aa","DOI":"10.1002\/eji.201040391"},{"doi-asserted-by":"crossref","unstructured":"Wang H, Dai Y, Qiu W, Lu Z, Peng F, Wang Y, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. Journal of Clinical Neuroscience. 2011;18(10):1313-7.10.1016\/j.jocn.2011.01.031","key":"2025120518082443756_j_bmc-2019-0007_ref_026_w2aab3b7b6b1b6b1ab1b6c26Aa","DOI":"10.1016\/j.jocn.2011.01.031"},{"doi-asserted-by":"crossref","unstructured":"Lin J, Li X, Xia J. Th17 cells in neuromyelitis optica spectrum disorder: a review. The International journal of neuroscience. 2016;126(12):1051-60.2695436310.3109\/00207454.2016.1163550","key":"2025120518082443756_j_bmc-2019-0007_ref_027_w2aab3b7b6b1b6b1ab1b6c27Aa","DOI":"10.3109\/00207454.2016.1163550"},{"doi-asserted-by":"crossref","unstructured":"Carboni S, Aboul-Enein F, Waltzinger C, Killeen N, Lassmann H, Pe\u00f1a-Rossi C. CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. Journal of neuroimmunology. 2003;145(1-2):1-11.10.1016\/j.jneuroim.2003.07.001","key":"2025120518082443756_j_bmc-2019-0007_ref_028_w2aab3b7b6b1b6b1ab1b6c28Aa","DOI":"10.1016\/j.jneuroim.2003.07.001"},{"doi-asserted-by":"crossref","unstructured":"Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1\u03b1 and IP-10 are expressed in demyelinating brain lesions. Proceedings of the National Academy of Sciences. 1999;96(12):6873-8.10.1073\/pnas.96.12.6873","key":"2025120518082443756_j_bmc-2019-0007_ref_029_w2aab3b7b6b1b6b1ab1b6c29Aa","DOI":"10.1073\/pnas.96.12.6873"},{"doi-asserted-by":"crossref","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Reviews Immunology. 2013;13(4):227.10.1038\/nri340523470321","key":"2025120518082443756_j_bmc-2019-0007_ref_030_w2aab3b7b6b1b6b1ab1b6c30Aa","DOI":"10.1038\/nri3405"},{"doi-asserted-by":"crossref","unstructured":"Gerondakis S, Siebenlist U. Roles of the NF-\u03baB pathway in lymphocyte development and function. Cold Spring Harbor perspectives in biology. 2010;2(5):a000182.20452952","key":"2025120518082443756_j_bmc-2019-0007_ref_031_w2aab3b7b6b1b6b1ab1b6c31Aa","DOI":"10.1101\/cshperspect.a000182"},{"unstructured":"I\u0142\u017cecka J. Serum soluble OX40 in patients with amyotrophic lateral sclerosis. Acta Clinica Croatica. 2012;51(1):3-6.22919996","key":"2025120518082443756_j_bmc-2019-0007_ref_032_w2aab3b7b6b1b6b1ab1b6c32Aa"},{"doi-asserted-by":"crossref","unstructured":"Pohl M, Kawakami N, Kitic M, Bauer J, Martins R, Fischer M-T, et al. T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta neuropathologica communications. 2013;1(1):85.10.1186\/2051-5960-1-85","key":"2025120518082443756_j_bmc-2019-0007_ref_033_w2aab3b7b6b1b6b1ab1b6c33Aa","DOI":"10.1186\/2051-5960-1-85"},{"doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez DA, D\u00edaz BB, P\u00e9rez MdCR, Hern\u00e1ndez AG, Chico BND, de Le\u00f3n AC. Sex hormones and autoimmunity. Immunology letters. 2010;133(1):6-13.2063723610.1016\/j.imlet.2010.07.001","key":"2025120518082443756_j_bmc-2019-0007_ref_034_w2aab3b7b6b1b6b1ab1b6c34Aa","DOI":"10.1016\/j.imlet.2010.07.001"},{"doi-asserted-by":"crossref","unstructured":"Djiki\u0107 J, Nacka-Aleksi\u0107 M, Pilipovi\u0107 I, Stoji\u0107-Vukani\u0107 Z, Bufan B, Kosec D, et al. Age-associated changes in rat immune system: lessons learned from experimental autoimmune encephalomyelitis. Experimental gerontology. 2014;58:179-97.10.1016\/j.exger.2014.08.00525128713","key":"2025120518082443756_j_bmc-2019-0007_ref_035_w2aab3b7b6b1b6b1ab1b6c35Aa","DOI":"10.1016\/j.exger.2014.08.005"}],"container-title":["Biomolecular Concepts"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/bmc\/10\/1\/article-p62.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/bmc-2019-0007\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/bmc-2019-0007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:41:02Z","timestamp":1764960062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/bmc-2019-0007\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,25]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,4,3]]},"published-print":{"date-parts":[[2019,4,3]]}},"alternative-id":["10.1515\/bmc-2019-0007"],"URL":"https:\/\/doi.org\/10.1515\/bmc-2019-0007","relation":{},"ISSN":["1868-503X","1868-5021"],"issn-type":[{"type":"electronic","value":"1868-503X"},{"type":"print","value":"1868-5021"}],"subject":[],"published":{"date-parts":[[2018,4,25]]}}}